TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05475392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Physical Therapy
Description: A 2-week physical therapy program will be arranged. Each patient will be given 60 min session , 10 min for neck ROMS (10 reps for each ROM) , 10 min neck Isometrics (5 reps on each side) , 30 sec static gentle stretch of levator scapulae (3reps) , 30 sec static gentle stretch of trapezius (3reps), 5 min Soft tissue manipulation , 5 min Shoulder shrugging (10reps) , 10 min for PIR

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: A 2-week physical therapy program will be arranged. Each patient will be given 60 min session , 10 min for neck ROMS (10 reps for each ROM) , 10 min neck Isometrics (5 reps on each side) , 30 sec static gentle stretch of levator scapulae (3reps) , 30 sec static gentle stretch of trapezius (3reps), 5 min Soft tissue manipulation , 5 min Shoulder shrugging (10reps) , 10 min for PIR

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Isometric Relaxation
Description: The exercise will be combined with the baseline treatment 3 sets PIR will be applied per session.The hypertonic muscle is taken to a length just short of pain, or to the point where resistance to movement is first noted. A submaximal (10-20%) contraction of the hypertonic muscle is performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction. The patient should inhale during this effort. After the isometric contraction, the patient is asked to relax and exhale while doing so. Following this, a gentle stretch is applied to take up the slack till the new barrier. Starting from this new barrier, the procedure is repeated two or three times.
Study: NCT06307080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-mode thermal ablation device
Description: The tumor tissue was rapidly frozen until the ice ball exceeded 5mm of the lesion tissue, kept for 5 minutes, then thawed and warmed. Then, complete ablation was performed according to the radiofrequency temperature control mode of multimodal tumor therapy to ensure that the ablation area included a safe range of 5\~10mm around the tumor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous anti-PD-1 and chemotherapy
Description: intravenous anti-PD-1 and chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous anti-PD-1 and chemotherapy
Description: intravenous anti-PD-1 and chemotherapy
Study: NCT04838444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA1553
Description: Trial participants previously vaccinated with VLA1553 in trial VLA1553-301 will be followed up for safety and immunogenicity.
Study: NCT05086952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) - Intervention A
Description: Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) - Intervention A
Description: Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) - Intervention A
Description: Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) - Intervention A
Description: Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) - Intervention B
Description: Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) - Intervention B
Description: Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) - Intervention B
Description: Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) - Intervention B
Description: Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) - Intervention C
Description: Single dose of 2.5 mg vericiguat low-concentration pediatric formulation (oral liquid formulation) in fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) - Intervention C
Description: Single dose of 2.5 mg vericiguat low-concentration pediatric formulation (oral liquid formulation) in fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) - Intervention C
Description: Single dose of 2.5 mg vericiguat low-concentration pediatric formulation (oral liquid formulation) in fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) - Intervention C
Description: Single dose of 2.5 mg vericiguat low-concentration pediatric formulation (oral liquid formulation) in fed state.
Study: NCT06161194

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised group exercise therapy
Description: Participants will participate in a 90 minutes supervised group exercise therapy program 2 times a week for 8 consecutive weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised group exercise therapy
Description: Participants will participate in a 90 minutes supervised group exercise therapy program 2 times a week for 8 consecutive weeks.
Study: NCT06329362

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive implantation
Description: Specially designed ridge splitting instrumentation by Champions Implant GmbH which is implant shaped expanders.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap procedure for ridge expansion.
Description: Mucoperiosteal elevation and ridge splitting using conventional ridge expanders.
Study: NCT04860713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin and ketamine
Description: Drug: Proprietary oral formulation of 0.85mg/kg of ketamine + 324mg of aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nurtec (Rimegepant)
Description: Drug: 75 mg of ODT
Study: NCT04866420

Intervention type: BEHAVIORAL
Intervention: The MenFAS Study
Description: A cross over repeated exposure randomized design observational study
Study: NCT05628233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SENS-401 (R-Azasetron Besylate)
Description: Patients will receive SENS-401 ((R)-azasetron besylate) B.I.D. up to 23 weeks: 1 week prior to the initiation of the cisplatin treatment, during the whole duration of the chemotherapy treatment (estimated to last up to 18 weeks) and 4 weeks after stopping chemotherapy.
Study: NCT05086952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (Verquvo, BAY1021189) - Intervention D
Description: Single dose of 10 mg vericiguat immediate release (IR) intact tablet in fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (Verquvo, BAY1021189) - Intervention D
Description: Single dose of 10 mg vericiguat immediate release (IR) intact tablet in fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (Verquvo, BAY1021189) - Intervention D
Description: Single dose of 10 mg vericiguat immediate release (IR) intact tablet in fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (Verquvo, BAY1021189) - Intervention D
Description: Single dose of 10 mg vericiguat immediate release (IR) intact tablet in fed state.
Study: NCT04907461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAPTAP
Description: Laparoscopic guided Transverse Abdominus Plane block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAPTAP
Description: Laparoscopic guided Transverse Abdominus Plane block
Study: NCT05236153

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Electroanatomic substrate mapping
Description: Participants will undergo a sinus rhythm RV substrate map using the HD Grid catheter (Abbott) and the Ensite X electroanatomic mapping system (Abbott) prior to TPVR.
Study: NCT06457048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stroke Unit
Description: The stroke unit at the University Teaching Hospital is a 12-bed unit on the general medical wards staffed by neurologists and nurses specifically trained in stroke care. This intervention includes new protocols and clinical practice guidelines that were developed by multiple stakeholders in Zambia to standardize stroke care, with a focus on early and consistent mobilization of patients with stroke, minimizing use of urinary catheters, provision of deep vein thrombosis prophylaxis, formal assessment of swallowing and assignment of modified diets as needed, and appropriate initiation of secondary prevention medications for stroke. Nurses and doctors working in this unit were trained on the new stroke unit protocols and are asked to follow these protocols in caring for patients with stroke admitted to the Stroke Unit.
Study: NCT05232097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Description: Diaphragmatic breathing exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Body awareness aiming at the patient becoming aware of the tensed thoracic and abdominal muscles and to reduce the tension by relaxation exercises taught by the psychophysical physiotherapist
Study: NCT04925414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxygenotherapy
Description: High concentration mask delivering 15L/min of oxygen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo air aerosol
Description: High concentration mask delivering 15L/min of air
Study: NCT05942885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anxiety questionnaire
Description: Patient undergoing hypnosis session will have their anxiety measured just before the third session of hypnosis and after during a telephonic consultation. The result will be compared to the anxiety level before the first hypnosis session
Study: NCT06380504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: R-SWITCH integrated intervention package
Description: 1. Monthly group meetings of Alliance for Development (AFD) community groups) and their members (caregivers of children 0-59 months of age):~   * Introduction and refresher of Family-led MUAC~  * Active screening of wasting by AFD~  * Group SBCC on Infant and Young Child Feeding (IYCF), health and Water, Sanitation and Hygiene (WaSH) with a focus on SAM~  * Promotion of health services such as GMP~2. Introduction of weight-for-age Z-score \<-3 as screening criterion for passive screening by health extension workers at any contact with children (e.g. during GMP)~3. Promotion of Family-led MUAC screening and SAM awareness to fathers during male agricultural/pastoralist extension activities and by community and religious leaders (creating social support)~4. Follow-up and counselling during home visits by AFD leaders of i) earlier referred cases of SAM, ii) cases enrolled in SAM OTP, iii) and recovered SAM cases discharged from OTP~5. Strengthening communication between HEW and AFDs
Study: NCT06525870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 85%TCA topical application
Description: 85%TCA topical application is done at cervical lesion and transformation zone. Application of TCA will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators. A thin film of TCA will be applied to cover the lesion and transformation zone.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 3% acetic acid
Description: 3% acetic acid topical application is done at cervical lesion and transformation zone. Application will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators. A thin film of acetic acid will be applied to cover the lesion and transformation zone.
Study: NCT05993767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen
Description: Switch or start dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen with a novel dose ratio for HIV treatment
Study: NCT05377034

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SIRT-Y90 with Atezolizumab + Bevacizumab
Description: Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by 1200mg atezolizumab + 15mg/kg bevacizumab administered by IV at every 3 weeks for 18 months.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SIRT-Y90 with Placebo (IV)
Description: Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by placebo at every 3 weeks for 18 months.
Study: NCT06313190

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Patients in both cohorts will receive SBRT using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3 fractions over 1 week.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic body radiotherapy
Description: Patients in both cohorts will receive SBRT using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3 fractions over 1 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Patients received sintilimab 200 mg every 3 weeks for up to 6 cycles, with the first dose within 1 week after the completion of SBRT.
Study: NCT06560918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aids
Description: OTC devices for a week
Study: NCT04803786

Intervention type: DRUG
Intervention: Transition from Xyrem to Xywav
Description: This is a single-group non-interventional study where participant's transitioning from Xyrem to Xywav will be observed. Investigational product (IP) or drug support or requested changes to their medication will not be provided to participants by Jazz Pharmaceuticals. The Xyrem and Xywav that the participants will take will be provided by the participant's health care provider.
Study: NCT04985773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lacrosse NSE ALPHA coronary dilatation catheter
Description: The Lacrosse NSE ALPHA is a rapid exchange percutaneous transluminal coronary angioplasty balloon catheter with non-slip element nylon threads that focus dilatation force to reduce balloon slippage during inflation.
Study: NCT06307015

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: De-escalation
Description: Surgical resection of primary oropharyngeal tumour followed by de-escalated radiation therapy (30Gy) with concurrent platinum-based chemotherapy to oropharynx + neck, followed by surgical neck dissection
Study: NCT05326373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stannous fluoride
Description: brush twice daily with stannous fluoride toothpaste for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stannous fluoride
Description: brush twice daily with stannous fluoride toothpaste for 8 weeks
Study: NCT04838821

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti SARS-CoV-2 equine hyperimmune serum
Description: All participants in the treatment groups will receive a single intravenous infusion on day 1 containing the specified dose according to their assigned group 12mg/kg, 30 mg/kg or 56mg/kg. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: All participants in the placebo group will receive a single intravenous infusion on day 1 containing a specified volume of a saline IV solution preparation. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
Study: NCT06307015

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Radiation therapy (70Gy) with concurrent platinum-based chemotherapy to oropharynx + neck
Study: NCT05457140

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic: Genomic sequencing and molecular diagnostic results, if any.
Description: Genomic sequencing results may be used for diagnosis and treatment of participants.
Study: NCT04860154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hematoporphyrin
Description: Patients with negative skin test of hematoporphyrin Injection (3.0-5.0mg/Kg plus saline 250 mL intravenous drip, the drip was completed within 1 hour) and keep patients away from the light. The first PDT therapy was performed 24 hours after infusion of hematoporphyrin injection by ERCP. The biliary tumor necrosis was observed and the biliary tract was cleaned up 24 hours later and then PDT therapy showed again if necessary. Multiple plastic stents or bald metal stents will be placed. Follow up regularly after the procedure, PDT therapy would be given again in 3 months.
Study: NCT05349396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3mg Test Drug T-1 Coated Tablets
Description: Participants will receive one tablet of the test formulation T-1 containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3mg Test Drug T-2 Coated Tablets
Description: Participants will receive one tablet of the test formulation T-2 containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone 3mg Reference Product Coated Tablets
Description: Participants will receive one tablet of the Rerefence Product containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
Study: NCT05457140

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)
Description: Whole Proteome programmable phage display immunoprecipitation sequencing will be used to diagnose known and novel autoantibodies.
Study: NCT06579391

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential amino acids
Description: Twice daily consumption for two weeks before and one week after surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanine
Description: Twice daily consumption for two weeks before and one week after surgery.
Study: NCT04886063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH-1017
Description: Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
Study: NCT05958225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEE Change Business and Personal Agency Training
Description: A three day residential training based on SEE Change's Empowered Entrepreneur Training curriculum. This training will be led by a certified SEE Change trained facilitator. The workshop will include individual and group exercises that allow participants to increase their self-awareness, build mental tools for resiliency and adaptability in their life, create life visions and key tools to create behavior change. Additional exercises will include specific business related content including record keeping, financial planning and marketing strategies based on the Business Model Canvas tool.~After the 3 day training, the participants will receive a supportive message through an interactive voice recording, once a week for 6 weeks. In addition, they will be contacted once a month, for three months (either by phone or in person) by the trainer to see how they are doing on their goals.
Study: NCT05886894

Intervention type: DEVICE
Intervention: Lotrafilcon B multifocal soft contact lenses
Description: Commercially available soft (hydrophilic) contact lenses indicated for the correction of presbyopia, with or without myopia or hyperopia

Intervention type: DEVICE
Intervention: Lotrafilcon B multifocal soft contact lenses
Description: Commercially available soft (hydrophilic) contact lenses indicated for the correction of presbyopia, with or without myopia or hyperopia

Intervention type: DEVICE
Intervention: Comfilcon A multifocal soft contact lenses
Description: Commercially available soft (hydrophilic) contact lenses indicated for the correction of refractive ametropia (myopia and hyperopia) and emmetropia with presbyopia

Intervention type: DEVICE
Intervention: Comfilcon A multifocal soft contact lenses
Description: Commercially available soft (hydrophilic) contact lenses indicated for the correction of refractive ametropia (myopia and hyperopia) and emmetropia with presbyopia
Study: NCT06196138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gum
Description: In the postoperative period, starting from the 4th hour, chewing gum is done 3 times a day, morning, noon and evening, for 30 minutes each, until the patient passes the first flatus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot Compress
Description: Starting from the 1st postoperative day, patients will receive hot application (to the lumbar region) for 10 minutes in the morning and evening. The hot application is applied by wrapping 2 towels in a water bag containing 55 ± 2 °C hot water. The water bag is applied to the lumbar region for 10 minutes with the patient in the supine position. The application is continued until the patient passes the first flatus.
Study: NCT05745883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DISC-0974
Description: DISC-0974 is administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DISC-0974
Description: DISC-0974 is administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered subcutaneously
Study: NCT05513508

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocolized rotational use of interfaces
Description: The NIV mask will be changed every 6 hours, alternating two different interfaces between the two most used in that center among those available i.e., oro-nasal, total face or hybrid mask.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Mask will be chosen according to the standard of care of the participating centers among the three types of masks available i.e., oro-nasal, total face or hybrid mask. Interface will be changed in case of discomfort judged by the patient as unbearable or in case of the presence of a pressure sore.
Study: NCT06568796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: randomize controlled study
Description: eswt treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: randomize controlled study
Description: eswt treatment